ProCE Banner Activity

The Importance of Biomarker Testing in NSCLC and Impact on Treatment

Clinical Thought

Expert faculty discuss the importance of comprehensive molecular profiling in NSCLC and the impact of actionable biomarkers on treatment selection.

Released: May 31, 2022

Expiration: May 30, 2023

No longer available for credit.

Share

Faculty

Rasheda Persinger

Rasheda Persinger, MSN, AGNP-C, AOCNP

Medical Oncology Lead Nurse Practitioner
Sidney Kimmel Cancer Center Sibley Memorial Hospital
Johns Hopkins System
Washington, DC

Beth Sandy

Beth Sandy, MSN, CRNP

Nurse Practitioner
Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennsylvania

Acknowledgement

This activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Supporters

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Target Audience

NPs and PAs in oncology

Disclosure

Rasheda Persinger, MSN, AGNP-C, AOCNP: consultant/advisor/speaker: AstraZeneca, Guardant Health, Pfizer.

Beth Sandy, MSN, CRNP: consultant: Amgen, AstraZeneca, Janssen, Jazz, Merck, Takeda.

None of the members of the Planning Committee or PCE staff have any relevant relationships to disclose.

Format

Clinical Thought

Disclaimer

The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.

Additional Information

Program Medium

This program has been made available online.